References
Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108:2509–19.
Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011;365:430–8.
Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367:11–9.
Desmond R, Townsley DM, Dumitriu B, Olnes MJ, Scheinberg P, Bevans M, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014;123:1818–25.
Yamazaki H, Ohta K, Iida H, Imada K, Obara N, Tokumine Y, et al. Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy. Int J Hematol. 2019;110:187–96.
Winkler T, Fan X, Cooper J, Desmond R, Young DJ, Townsley DM, et al. Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag. Blood. 2019;133:2575–85.
Townsley DM, Scheinberg P, Winkler T, Desmond R, Dumitriu B, Rios O, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N. Engl J Med. 2017;376:1540–50.
Tomiyama Y, Jang JH, Lee J-W, Miyazaki K, Nagafuji K, Usuki K, et al. Efficacy and safety of romiplostim in patients with acquired aplastic anemia ineligible or refractory to immunosuppressive therapy: interim analysis of phase 2/3 clinical trial. Blood. 2018;132 (Suppl. 1):1306.
Zhao LP, Sicre De Fontbrune F, Contejean A, Abraham J, Terriou L, Chabrot C, et al. Nationwide survey in France on the use of romiplostim in patients with refractory severe aplastic anemia. Bone Marrow Transpl. 2019;54:1161–3.
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 2013;48:452–8.
Lee JW, Lee SE, Jung CW, Park S, Keta H, Park SK, et al. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial. Lancet Haematol. 2019;6:e562–72.
Zhao Z, Sun Q, Sokoll LJ, Streiff M, Cheng Z, Grasmeder S, et al. Eltrombopag mobilizes iron in patients with aplastic anemia. Blood. 2018;131:2399–402.
Kao YR, Chen J, Narayanagari SR, Todorova TI, Aivalioti MM, Ferreira M, et al. Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag. Sci Transl Med. 2018;10:eaas9563.
Acknowledgements
The authors thank Rie Ohmi (Kanazawa University) for her excellent technical assistance. We thank all patients and medical staff of participating institutions who contributed to this study. We are grateful to the following doctors for providing us with clinical information: K. Aoshima of Houju Memorial Hospital; Y. Kaneko of Saitama Cancer Center; H. Shibayama and T. Yokota of Osaka University Hospital; K. Shirahata of Iida Municipal Hospital; T. Ono of Hamamatsu University Hospital; M. Okura of University of Fukui Hospital; M. Ogata of Oita University Hospital; T. Endo of Hokkaido University Hospital; T. Kitano of Kitano Hospital; K. Miyazaki of Kitasato University Hospital; Y. Kageyama of Kuwana City Medical Center; T. Yamaguchi of Mie University Hospital; and M. Takeuchi of Kohka Public Hospital. This study was supported by a MEXT Grant-in-Aid for Scientific Research (B, 19H03686 to SN, C, 18K08318 to HY and Young Scientists, 19K17823 to KH).
Author information
Authors and Affiliations
Contributions
KH, HY, and SN designed the research, analyzed the data, and wrote the manuscript. KH, HY, MT, TI, NS, and SN recruited patients to participate in the study. All authors critically reviewed the manuscript and approved the submission of the final manuscript. KH and HY equally contributed to this paper as first authors.
Corresponding author
Ethics declarations
Conflict of interest
HY received research funding from Otsuka Pharmaceutical and Alexion Pharma, and honoraria from Novartis Pharma, Kyowa Kirin, Sanofi, Nippon Shinyaku, Chugai Pharmaceutical and Fuji Pharma. SN received honoraria fees and lecture fees from Novartis Pharma K.K. and Kyowa-Kirin K.K. KH, MT, TI, and NS declare that they have no conflicts of interest to report.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Hosokawa, K., Yamazaki, H., Tanabe, M. et al. High-dose romiplostim accelerates hematologic recovery in patients with aplastic anemia refractory to eltrombopag. Leukemia 35, 906–909 (2021). https://doi.org/10.1038/s41375-020-0950-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-020-0950-6
- Springer Nature Limited
This article is cited by
-
Late graft failure with donor-derived GPI-deficient cells in a mixed chimera following allogeneic bone marrow transplantation for severe aplastic anemia
Bone Marrow Transplantation (2023)
-
Aplastische Anämie
InFo Hämatologie + Onkologie (2021)
-
Eltrombopag/romiplostim
Reactions Weekly (2021)